Allergan Sues Hi-Tech To Block Generic Lash Drug Latisse

Law360, New York (May 16, 2012, 7:17 PM EDT) -- Allergan Inc. filed its third patent infringement suit against Hi-Tech Pharmacal Co. Inc. in North Carolina federal court on Wednesday, its latest effort to block a generic version of the eyelash growth treatment Latisse.

Allergan claims Hi-Tech's abbreviated new drug application seeking permission to manufacture bimatoprost ophthalmic solution infringes its patent for the drug. The treatment is marketed as Latisse, which was released in December 2008 as a treatment for hypotrichosis of the eyelashes and has become popular with consumers who want longer or thicker lashes....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.